Although these differences did not reach statistical significance, the data suggest a potential clinical benefit of immunotherapy in patients with higher PD-L1 expression.
← all excerpts
The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.
1
—
—